Literature DB >> 7159921

Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations.

V Ala-Hurula, V Myllylä, E Hokkanen.   

Abstract

Twenty-three patients suffering from continuous headache linked with habitual daily use of ergotamine tartrate were studied. Their headaches were classified clinically, and possible side effects of ergotamine medication, plasma levels of ergotamine, and occurrence of withdrawal symptoms after discontinuation of drug abuse were recorded. Seventeen of the patients were clinically diagnosed as suffering from "ergotamine headache", and seven of them complained of coldness in the extremities. Plasma ergotamine levels were measured by using a radioimmunoassay. In almost half of the patients the 1 h plasma levels after the daily dose were below the detection limit of the procedure (0.12 ng/ml). The duration and severity of the withdrawal symptoms did not correlate with the doses and plasma levels of ergotamine. In only 4 of the 21 patients who were followed up for 3 to 6 months did headache symptoms not improve after ergotamine withdrawal. The results indicate that even small (0.5-1.0 mg/day) doses of ergotamine tartrate taken regularly may cause continuous headache symptoms and withdrawal symptoms after discontinuation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159921     DOI: 10.1046/j.1468-2982.1982.0204189.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Analgesic-induced chronic headache: long-term results of withdrawal therapy.

Authors:  H C Diener; J Dichgans; E Scholz; S Geiselhart; W D Gerber; A Bille
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

Review 2.  Drug overuse and rebound headache.

Authors:  Stephen D Silberstein; Dongmei Liu
Journal:  Curr Pain Headache Rep       Date:  2002-06

Review 3.  Analgesic rebound headache. How great is the problem and what can be done?

Authors:  S D Silberstein; W B Young
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

4.  Upper limb artery segmental occlusions due to chronic use of ergotamine combined with itraconazole, treated by thrombolysis.

Authors:  Edoardo Cervi; Stefano Bonardelli; Giuseppe Battaglia; Federico Gheza; Roberto Maffeis; Franco Nodari; Roberto Maroldi; Stefano M Giulini
Journal:  Thromb J       Date:  2011-08-30

Review 5.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Long-term maintenance of improvements achieved with (abortive) pharmacological and nonpharmacological treatments for migraine: preliminary findings.

Authors:  K A Holroyd; J F Holm; D B Penzien; G E Cordingley; K G Hursey; N J Martin; A Theofanous
Journal:  Biofeedback Self Regul       Date:  1989-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.